CASI Pharmaceuticals announced that the FDA has placed a clinical hold on its CID-103, an anti-CD38 antibody for the treatment of Antibody Mediated Rejection (AMR) in kidney transplant patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback